Literature DB >> 18072762

Epoxidation and 1,2-dihydroxylation of alkenes by a nonheme iron model system - DFT supports the mechanism proposed by experiment.

Peter Comba1, Gopalan Rajaraman.   

Abstract

The FeII complexes of two isomeric pentadentate bispidine ligands in the presence of H2O2 are catalytically active for the epoxidation and 1,2-dihydroxylation of cyclooctene (bispidine = 3,7-diazabicyclo[3.3.1]nonane; the two isomeric pentadentate bispidine ligands discussed here have two tertiary amine and three pyridine donors). The published spectroscopic and mechanistic data, which include an extensive set of 18O labeling experiments, suggest that the FeIV=O complex is the catalytically active species, which produces epoxide as well as cis- and trans-1,2-dihydroxylated products. Several observations from the published experimental study are addressed with hybrid density functional methods and, in general, the calculations support the proposed, for nonheme iron model systems novel mechanism, where the formation of a radical intermediate emerges from the reaction of the FeIV=O oxidant and cyclooctene. The calculations suggest that the S = 1 ground state of the FeIV=O complex reacts with cyclooctene in a stepwise reaction, leading to the formation of a carbon-based radical intermediate. This radical is captured by O2 from air to produce the majority of the epoxide products in an aerobic atmosphere. Under anaerobic conditions, the produced epoxide product is due to the cyclization of the radical intermediate. Several possible spin states (ST = 3, 2, 1, 0) of the radical intermediate are close in energy. As a result of the substantial energy barrier, calculated for the ST = 3 spin ground state, a spin-crossover during the cyclization step is assumed, and a possible two-state scenario is found, where the S = 2 state of the FeIV=O complex participates in the catalytic mechanism. The 1,2-dihydroxylation proceeds, as suggested by experiment, via an unprecedented pathway, where the radical intermediate is captured by a hydroxyl radical, the source of which is FeIII-OOH, and this reaction is barrierless. The calculations suggest that dihydroxylation can also occur by a direct oxidation pathway from FeIII-OOH. The strikingly different reactivities observed with the two isomeric bispidine FeII complexes are rationalized on the basis of structural and electronic differences.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18072762     DOI: 10.1021/ic701161r

Source DB:  PubMed          Journal:  Inorg Chem        ISSN: 0020-1669            Impact factor:   5.165


  5 in total

1.  Modeling the cis-oxo-labile binding site motif of non-heme iron oxygenases: water exchange and oxidation reactivity of a non-heme iron(IV)-oxo compound bearing a tripodal tetradentate ligand.

Authors:  Anna Company; Irene Prat; Jonathan R Frisch; Ruben Mas-Ballesté; Mireia Güell; Gergely Juhász; Xavi Ribas; Eckard Münck; Josep M Luis; Lawrence Que; Miquel Costas
Journal:  Chemistry       Date:  2011-01-05       Impact factor: 5.236

2.  Iron-catalyzed asymmetric epoxidation of β,β-disubstituted enones.

Authors:  Yasuhiro Nishikawa; Hisashi Yamamoto
Journal:  J Am Chem Soc       Date:  2011-05-16       Impact factor: 15.419

Review 3.  Oxidation of alkane and alkene moieties with biologically inspired nonheme iron catalysts and hydrogen peroxide: from free radicals to stereoselective transformations.

Authors:  Giorgio Olivo; Olaf Cussó; Margarida Borrell; Miquel Costas
Journal:  J Biol Inorg Chem       Date:  2017-01-25       Impact factor: 3.358

4.  Enhanced Rates of C-H Bond Cleavage by a Hydrogen-Bonded Synthetic Heme High-Valent Iron(IV) Oxo Complex.

Authors:  Melanie A Ehudin; David A Quist; Kenneth D Karlin
Journal:  J Am Chem Soc       Date:  2019-08-02       Impact factor: 15.419

5.  A comprehensive test set of epoxidation rate constants for iron(iv)-oxo porphyrin cation radical complexes.

Authors:  Mala A Sainna; Suresh Kumar; Devesh Kumar; Simonetta Fornarini; Maria Elisa Crestoni; Sam P de Visser
Journal:  Chem Sci       Date:  2014-12-08       Impact factor: 9.825

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.